BasemMourad LabibMishrikyMD
Internal Medicine • Raleigh, NCFellowship-trained Diabetologist, Obesity Medicine Specialist
Dr. Mishriky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7200 Creedmoor Rd
Suite 208
Raleigh, NC 27613Phone+1 919-701-5157
Summary
- Fellowship trained in Diabetes at Vidant Medical Center / East Carolina University from July 2016 till June 2017. I was mentored by a great mentor, Dr. Robert Tanenberg.
Through my passion in diabetes, I practice in a specialized diabetes clinic at ECU Physicians to serve patients with type 1 diabetes, type 2 diabetes, gestational diabetes, patients on insulin pumps, patients with insulin resistance, patients on continuous glucose monitor (CGM), and diabetic neuropathy.
Education & Training
ECU Health Medical Center/East Carolina UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 2016 - 2017
ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2014 - 2016- ECU Health Medical Center/East Carolina UniversityInternship, Internal Medicine, 2013 - 2014
Cairo University School of MedicineClass of 2007
Certifications & Licensure
NC State Medical License 2013 - 2025
SC State Medical License 2022 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- Teaching Recognition Award by 3rd Year Medical Residents East Carolina University, 2019
- Teaching Recognition Award by 2nd Year Medical Residents East Carolina University, 2018
- Best Clincal Research Poster Annual North Carolina ACP, 2017
- Join now to see all
Clinical Trials
- Trial to Assess Chelation Therapy 2 Start of enrollment: 2016 Oct 01
- A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs Start of enrollment: 2017 Mar 13
Publications & Presentations
PubMed
- Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empaglifloz...Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacqueline R Halladay, Schuyler Jones
Diabetes, Obesity & Metabolism. 2024-05-01 - 1 citationsA meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit?Basem M Mishriky, Doyle M Cummings, James R Powell
Diabetes/metabolism Research and Reviews. 2024-01-01 - 8 citationsDiabetes-Related Microvascular Complications - A Practical Approach.Basem M Mishriky, Doyle M Cummings, James R Powell
Primary Care. 2022-06-01
Press Mentions
CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADAJuly 13th, 2019
Do Black Patients with Type 2 Diabetes Gain Cardiac Benefit from the SGLT2 and GLP-1 Drugs?June 25th, 2019
CV Benefit of Newer Type 2 Diabetes Drugs Not Seen in Black PatientsMarch 24th, 2019
Professional Memberships
- Member
- Member
- Endocrine SocietyMember
- American College of DiabetologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
